Business
MedMira Awarded China Patent to Complete IP Triple Crown
Rapid Flow-Through Technology Patents in Three Major Global Markets HALIFAX, July 21 /CNW/ - MedM...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n\nRapid Flow-Through Technology Patents in Three Major Global Markets\n\n\nHALIFAX, July 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today\nthat it received a Notice on Grant of Patent Right For Invention (equivalent\nto the Notice of Allowance in the United States) from the State Intellectual\nProperty Office (SIPO) of the People's Republic of China for its rapid\ndiagnostic device and assay (Chinese Patent Application No. 02819646.5). The\nnovel invention is the rapid flow-through technology (RFT) platform, the core\nproduct engine upon which the company has built its successful line of rapid\ntests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's\nIP "triple crown" along with similar patents awarded in the United States\n(Patent Application No. 10/163,675) and the European Union (European Patent\nNo. EP1417489).\n\n\n"Patents on our core technology in three major global markets are\nfundamental components of our plan to grow our business through strategic\npartnerships. While we continue to pursue patent protection for our\nprogressive IP estate in additional markets, we can now fully engage in\ncollaborative relationships to tap opportunities in three of the most\nlucrative markets of the $40 billion global diagnostics market," said Hermes\nChan, President and CEO, MedMira Inc. "These partnerships, taking shape in\nvarious forms including licensing, commercialization, and contract\nmanufacturing, will enable both new business and new innovation opportunities\nfor MedMira."\n\n\nThrough straightforward and affordable licensing agreements MedMira\noffers its patented technology platform to diagnostics developers seeking a\nclear path to the global diagnostics market. While other technologies pose\npotential roadblocks for developers, MedMira provides a comprehensive, proven\nsolution. The rapid flow-through technology is the core innovation behind\nMedMira's fully commercialized line of rapid tests. The tests can be used to\ndiagnose one or multiple diseases using one test device and a single drop of\nspecimen. MedMira's rapid tests have performed exceptionally well in rigorous\nclinical trials, earning "gold standard" regulatory approvals in major\ninternational ...